![PDF) The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis PDF) The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis](https://i1.rgstatic.net/publication/347722353_The_risk_of_polypharmacy_comorbidities_and_drug-drug_interactions_in_women_of_childbearing_age_with_multiple_sclerosis/links/60159d9aa6fdcc071ba4c9d6/largepreview.png)
PDF) The risk of polypharmacy, comorbidities and drug–drug interactions in women of childbearing age with multiple sclerosis
![PDF) Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosis PDF) Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosis](https://i1.rgstatic.net/publication/273009812_Economic_impact_of_new_active_substance_status_on_EU_payers'_budgets_example_of_dimethyl_fumarate_TecfideraR_for_multiple_sclerosis/links/57bd7fd808ae6918243022d4/largepreview.png)
PDF) Economic impact of new active substance status on EU payers' budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosis
![S. Cook's research works | Rutgers, The State University of New Jersey, NJ (Rutgers) and other places S. Cook's research works | Rutgers, The State University of New Jersey, NJ (Rutgers) and other places](https://www.researchgate.net/profile/Rupert_Sandbrink/publication/51493339/figure/tbl2/AS:669356539256833@1536598443040/Functional-Assessment-of-Multiple-Sclerosis-Scale-acceptability-and-internal_Q320.jpg)
S. Cook's research works | Rutgers, The State University of New Jersey, NJ (Rutgers) and other places
![Market Access strategy for new MS product in the Netherlands - Consultancy in Healthcare and Life Sciences | Vintura Consultancy Market Access strategy for new MS product in the Netherlands - Consultancy in Healthcare and Life Sciences | Vintura Consultancy](https://www.vintura.com/wp-content/uploads/2016/08/160003177_Vintura_Beelden_Website_1440x550_03_v01.jpg)
Market Access strategy for new MS product in the Netherlands - Consultancy in Healthcare and Life Sciences | Vintura Consultancy
![Ozanimod for Relapsed MS: Researchers Confirm Safety of Recently Approved S1P Modulator - Physician's Weekly Ozanimod for Relapsed MS: Researchers Confirm Safety of Recently Approved S1P Modulator - Physician's Weekly](https://cdn.atpoc.com/cdn/activity/breakingmed/image/84582.jpeg)